Background: Faecal microbiota transplantation (FMT) is emerging as a novel therapy
In recent years, faecal microbiota transplant (FMT) has been proven to be extremely effective for treatment of recurrent or refractory Clostridium difficile infection (CDI). [8] [9] [10] [11] [12] [13] [14] This has encouraged research in FMT as a potential therapy for other microbial-related diseases such as UC. FMT is proposed as a means of altering the disease process by modifying the colonic ecosystem and thus the potential biochemical and antigenic drivers of the disease.
Since the first case of FMT for the treatment of UC was described by Justin Bennet in 1989, 15 there have been a number of case reports, case series, and more recently, randomized controlled trials (RCTs). To assimilate these data, we conducted a systematic review and meta-analysis to assess the efficacy and safety of FMT for induction of remission in active UC.
2 | ME TH ODS
| Search strategy
A systematic search and retrieval of records was performed in accordance with the MOOSE, PRISMA and Cochrane guidelines. [16] [17] [18] We searched Medline (1948 -February 2017 , EMBASE (1948 -February 2017 ) and the Cochrane Inflammatory Bowel Disease/ Functional Bowel Disorders review group specialist trials register without language restriction from inception through February 2017.
Abstracts from major meetings in gastroenterology and inflammatory bowel diseases (IBD) were searched manually and assessed for relevance. These included Digestive Disease Week (2010-2016), Congress of the European Crohn's and Colitis Organisation (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) and the United European Gastroenterology Week (2010) (2011) (2012) (2013) (2014) (2015) (2016) . Bibliographies of review articles and meta-analyses [19] [20] [21] were searched to identify additional studies. Searching was limited to publications with human subjects. Articles in English and Mandarin were reviewed and other languages excluded.
An initial database search using the key words "fecal", "faecal", "microbiota", "microflora", "feces", "faeces", "stool", "fecal flora" and "faecal flora" was performed. Subsequently, each key word was combined with each of the following variations on transplant: "transplant", "enema", donor", "infusion", "transfusion", "implant" "implantation" and "instillation". These terms were searched in combination and "bacteriotherapy" searched for individually. The results were combined with terms for UC using the Boolean term "AND": "ulcerative colitis" "inflammatory bowel disease", "colitis", "IBD" or "UC". This strategy was used both as Medical Subject Headings (MeSH) terms if available and as free text. Variations of root word were also searched alone or in combination. Two authors independently reviewed all articles other than articles in Mandarin that were reviewed by WS alone and then discussed together with SPC.
| Study Selection
Eligible studies were RCTs and cohort studies that investigated FMT as induction of remission for active UC in both paediatric and adult patients with clearly described measures of remission.
Studies were excluded if enrolled patients did not have clearly defined active disease, there was no definition of remission, clinical endpoints were not reported, or the study included only patients with comorbid infections such as CDI. Studies that included patients with concomitant infections were considered only if the data from patients with UC and without infection could be clearly delineated from those with infection.
The Cochrane risk of bias tool 18 was used to assess for bias in RCTs (Table S2) . Data were extracted into a Microsoft Excel for Mac 2011 (Microsoft, Redmont, AL, USA). Risk of bias of the cohort studies was assessed using a modified Newcastle-Ottawa scale for cohort studies. The scale was adjusted for use in cohort studies without a control group. This was adjusted to a six-point scale after questions that assessed for control groups were removed (Table S1 ).
Two investigators (SPC and WS) independently completed the Cochrane risk of bias tool for RCTs and the inter-investigator agreement was 100% (Cohen's kappa = 1.0). The inter-investigator agreement on meeting the inclusion criteria for the observational studies was 88% (Cohen's kappa = 0.75). Consensus was reached by combined review of any studies (n=4), where there had been initial discrepancy. Only RCTs were included in the meta-analysis to provide a pooled remission and response rate for FMT for induction of remission in UC.
| Data extraction
Full text articles and conference abstracts that met inclusion criteria were reviewed by SPC and WS to identify study characteristics such as study type, patient characteristics (Table 1) , FMT processing methods and delivery protocols (Table 4) as well as clinical remission   and response rates and definitions (Tables 2 and 3 ).
| Statistical analysis
For RCTs, a random effects model was used to assess the pooled estimate of remission, clinical response and endoscopic remission in the meta-analysis using Review Manager 5. 3 | RESULTS
| Search results
The initial search revealed 2072 potential articles. After screening titles and abstracts, 44 studies remained after duplicates were removed. After review of full text articles and abstracts, 18/44 were eligible for inclusion, consisting of four RCTs and 14 cohort studies ( Figure 1 ).
| Cohort studies
There were 14 cohort studies [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] that included a total of 168 patients (Tables 1 and 2 
| Pooled Remission and response rates
The endpoints reported in each RCT varied. Definitions used in each study are shown in Table 3 . FMT than those with UC for longer. 37 However, UC duration prior to FMT was not associated with remission in two other studies.
39,40
The Rossen et al. study was terminated early due to an interim futility analysis as it was powered to detect a treatment effect of 70%.
This study showed no significant difference between donor and placebo groups on intention-to-treat (ITT) analysis (30.4% vs 20%) P=.51.
The other three studies each demonstrated statistically significant benefit of donor FMT over placebo for induction of remission in UC.
Clinical response was achieved in 69/140 patients (49%) who 
| Stool processing
The method of stool processing varied between trials ( 
| Safety
Adverse events were monitored and reported in each study. Overall, FMT was well tolerated. The most common serious adverse event reported was worsening colitis, which occurred in 3/140 patients in donor arms (with one colectomy) and 4/137 patients in the placebo arms. There were three cases of small bowel Crohn's disease subsequently reported and two cases of C. difficile colitis with one requiring colectomy in donor arms. In the placebo arms, there was one case each of Crohn's disease, primary cytomegalovirus infection and cervical cancer (unrelated). Two studies reported adverse events more extensively with 50/63 (79%) in the donor arms and 49/65 (75%) in the placebo arms having at least one adverse event. 38, 39 The most common adverse events were self-limiting gastrointestinal complaints.
There were no significant differences between number or type of adverse event between donor and placebo groups in either study.
| Microbiome changes
Rossen et al. showed that compared with donors, pre-FMT UC patients had significantly lower abundance of members of Clostridium cluster IV, XIVa and XVIII and higher abundance of Bacteroidetes, Bacilli, Proteobacteria and Clostridium clusters IX and XI. 38 The stool microbial diversity of UC patients and donors did not differ at baseline, however, the Shannon diversity index for responders increased significantly following FMT. Redundancy analysis showed that the microbiota composition of responders in the donor FMT group shifted from overlap with non-responders at baseline to healthy donors at week 12. This shift was mainly explained by regain of Clostridium clusters IV, XIVa and XVIII and reduction in Bacteroidetes. 38 Moayyedi et al. found an enrichment for the family Lachnospiraceae and the genera Ruminococcus in a particular donor who was associated with most cases (7/9, 78%) of remission. 37 When similarity was compared between the active cohort after FMT and their respective donors, there was a statistically significant effect of the active therapy group being more similar to their donor than to a control faecal sample.
Paramsothy et al. found that those patients who went on to achieve remission had a greater diversity at both baseline and following FMT. In their study, achieving remission following FMT was associated with gains in Ruminococcus, Clostridium cluster IV and XVIII, Barnesiella spp, Blautia spp, Dorea spp and Parabacteroides spp. Conversely, the presence of Fusobacterium spp and Sutterella spp following FMT were associated with no remission. (Table 5) . (Figure 2) . [37] [38] [39] [40] This effect appears to be robust as it is seen despite variation in stool processing and delivery methods between the trials. In addition, no major short term safety signals were observed.
Each trial used different stool delivery protocols and donor stool processing methods which makes it difficult to recommend a particu- that of a single donor. 39 Pooling stool may result in a greater chance that an important element of stool will be transmitted to the recipient. However, it is not clear whether this theoretical benefit translates to improved efficacy, and using pooled stool requires blending and does add some logistical complexity to the manufacturing process. 41 The four RCTs had different intensities of FMT delivery and this has implications for the real world feasibility of use for of FMT for UC ( however they did not demonstrate a significant difference in remission rates over placebo. 38 It appears that a short duration of therapy may be sufficient for remission induction in some patients. These studies do not, however, provide data on the longevity of the treatment response, long-term safety or the possible ability to maintain remission with interval dosing.
T A B L E 3 Study characteristics of Randomised Controlled Trials of FMT for UC
Rossen et al. 38 Moayyedi et al. 37 Paramsothy et al. 39 Costello et al. 40 Patients enrolled (Donor/ Placebo) Odds Ratio IV, Random, 95% CI F I G U R E 2 Forest plot for remission in randomised controlled trials of faecal microbiota transplant (FMT) for ulcerative colitis. Remission was variably defined as per Table 3 influence bacterial viability and therefore bacterial engraftment into the colonic ecosystem. 45 For example, Faecalibacterium prausnitzii, a bacterium frequently associated with colonic health is extremely oxygen sensitive. 46 The choice of placebo agent in FMT studies may have an influence on trial results. A water placebo is likely to be hypotonic and recognisably different to faeces to both the administrator and recipient of FMT, and therefore has the capacity to bias results (Table S2) .
To try to mitigate this issue, Moayyedi et al. had a person not involved in the assessment of patients deliver the FMT enemas 37 and Paramsothsy et al. used a fluid discolourant and odorant. 39 Autologous stool is likely to represent a better placebo than water, however, through the process of faecal processing and freezing, the recipient's own stool composition will also be altered. A recent FMT study for the treatment of CDI had a high placebo response and there is the possibility that processing and storage of the autologous stool could have influenced the placebo response. 11 The Rossen and Paramsothy studies had central reading of the colonoscopy images, which minimises bias in the blinding of outcome, the other RCT did not use central reading of colonoscopy images.
37-40
Study FMT, faecal microbiota transplantation; UC, Ulcerative colitis; g, grams; w, week.
The optimal route of FMT delivery in UC, whether via the upper or lower gastrointestinal tract is uncertain, although it is likely to influence the success of the procedure. In favour of lower GI delivery of FMT in UC, the three positive RCTs to date employed lower GI delivery techniques, and upper GI delivery was used in the only negative RCT identified. Furthermore, systematic review of FMT for the treatment of CDI demonstrated that colonoscopic delivery has higher rates of success than other delivery methods for this indication. 47 However, the rate of clinical remission in the UC cohort and RCT studies combined is similar between upper GI delivery 11/42 (26%) and lower GI delivery 63/252 (25%). This may include the delivery of FMT or rationally designed microbial therapeutics via capsule as research and development into these technologies is already underway. [48] [49] [50] In addition to efficacy, patient acceptability of any delivery method is important to the success of FMT therapy. Clearly, further research is needed to elucidate the optimal route of FMT administration.
Stool is a nonstandardised product with stool composition differing between individual donors and even from sample to sample from the same donor. 51 It is possible that certain donors may provide stool that is more or less efficacious than others and this could affect individual trial results. For instance, Moayyedi et al. found that the majority of the treatment effect observed related to one particular "super donor". 37 This particular donor had a relative enrichment of the genus Lachnospiraceae and Rumunococcus. There are observable changes in bacterial phyla following FMT (Table 5) Prolonged frozen storage will increase the Firmicutes to Bacteroidetes ratio as some of the gram-negative species are more fragile and deplete during frozen storage. 52 There may therefore be a theoretical benefit to frozen over fresh stool if elements of the Firmicutes phyla are relatively beneficial compared to elements of the Bacteroidetes. Patients in the Rossen et al. study that did not demonstrate efficacy were treated with fresh stool 38 and the majority of the patients who achieved remission in the other RCTs were treated with frozen stool. 37, 39, 40 There was also a higher rate of remission reported in the cohort studies using frozen stool (30%) vs fresh stool (22%).
Given the success of FMT as an agent to induce remission in UC, there is now a need to investigate the mechanisms by which this effect is achieved. There are shifts in the microbial composition following FMT with increased diversity as well as more specific changes in bacterial phyla, particularly in responders. 39 
